Displaying drugs 15276 - 15300 of 15477 in total
1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
Experimental
SR 121463
SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion …
FT-1101
FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Investigational
Matched Description: … FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. …
Dipipanone
Experimental
Illicit
2,3,4,5,6-Pentafluorobenzyl Alcohol
Experimental
Iodobenzene
Experimental
ES-936
Experimental
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
Experimental
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
Experimental
4-Fluorophenethyl Alcohol
Experimental
1,3,5-trichlorobenzene
Experimental
N-(Chlorophenyl)-N'-hydroxyguanidine
Experimental
(R)-4-Nitrostyrene oxide
Experimental
Seproxetine
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and …
1-[4-(hydroxymethyl)phenyl]guanidine
Experimental
1-(4-thiophen-2-ylphenyl)methanamine
Experimental
4-(2-aminoethyl)-2-ethylphenol
Experimental
Displaying drugs 15276 - 15300 of 15477 in total